{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:18:06Z","timestamp":1781086686156,"version":"3.54.1"},"reference-count":83,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Over the past two decades, the incidence of cancer-associated thrombosis (CAT) has increased. It is nowadays a common and often serious complication among patients with cancer. Although medical thromboprophylaxis is recommended for most surgical and nonsurgical cancer patients, it has been infrequently used in ambulatory patients with cancer because of the burden of treatment and concerns about bleeding. However, various risk assessment scores are now available and randomized placebo-controlled trials have established the efficacy of low-molecular-weight heparin or the direct oral Xa inhibitors rivaroxaban and apixaban in ambulatory patients with cancer at high risk of venous thromboembolism (VTE). This review provides an overview of (1) primary thromboprophylaxis in the setting of hospitalized surgical and medical patients, (2) extended thromboprophylaxis after hospital discharge, (3) performance of risk assessment tools for CAT, and (4) primary thromboprophylaxis in ambulatory patients with cancer. The aim is to provide support to physicians in identifying ambulatory patients with cancer at high VTE risk who benefit most from medical thromboprophylaxis according to current recommendations from international guidelines.<\/jats:p>","DOI":"10.1055\/a-2374-3425","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T23:27:57Z","timestamp":1728602877000},"page":"127-138","source":"Crossref","is-referenced-by-count":3,"title":["Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives"],"prefix":"10.1055","volume":"45","author":[{"given":"Christina","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"van Es","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC location, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Voigtlaender","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"14","key":"ref1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"S 01","key":"ref2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2022.01.004","article-title":"Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies","volume":"213","author":"F Moik","year":"2022","journal-title":"Thromb Res"},{"issue":"S 01","key":"ref3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0049-3848(20)30389-3","article-title":"Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future","volume":"191","author":"F Moik","year":"2020","journal-title":"Thromb Res"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","article-title":"Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study","volume":"98","author":"B Dickmann","year":"2013","journal-title":"Haematologica"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.27222","article-title":"Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"99","author":"D C Roy","year":"2024","journal-title":"Am J Hematol"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/jth.15250","article-title":"Pulmonary embolism at autopsy in cancer patients","volume":"19","author":"I A Gimbel","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"A A Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"A A Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"25","key":"ref9","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"H T S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"F Moik","year":"2021","journal-title":"Blood"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/bloodadvances.2022009577","article-title":"Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study","volume":"7","author":"M JT Crobach","year":"2023","journal-title":"Blood Adv"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/jth.15739","article-title":"Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma","volume":"20","author":"F HJ Kaptein","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"101350","DOI":"10.1016\/j.beha.2022.101350","article-title":"Challenges in anticoagulation for patients with brain tumors","volume":"35","author":"V Iyengar","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/OTT.S166151","article-title":"Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials","volume":"11","author":"B Xiao","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/a-2188-8773","article-title":"Risk factors for bleeding in cancer patients treated with conventional dose followed by low-dose apixaban for venous thromboembolism","volume":"124","author":"P Hussaini","year":"2024","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-02-0125","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism","volume":"100","author":"J Trujillo-Santos","year":"2008","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jvs.2011.10.129","article-title":"Variation in thromboembolic complications among patients undergoing commonly performed cancer operations","volume":"55","author":"R R De Martino","year":"2012","journal-title":"J Vasc Surg"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archinte.164.9.963","article-title":"Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study","volume":"164","author":"R Alikhan","year":"2004","journal-title":"Arch Intern Med"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12885-016-3032-4","article-title":"Incidence of Venous Thromboembolism in cancer patients treated with cisplatin based chemotherapy - a cohort study","volume":"17","author":"M N Zahir","year":"2017","journal-title":"BMC Cancer"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1080\/10428194.2022.2102621","article-title":"Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia","volume":"63","author":"P Dharia","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study","volume":"6","author":"C White","year":"2019","journal-title":"Lancet Haematol"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2016-12-758995","article-title":"Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US","volume":"130","author":"J A Heit","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jvs.2006.10.034","article-title":"Risk factors and clinical impact of postoperative symptomatic venous thromboembolism","volume":"45","author":"C Gangireddy","year":"2007","journal-title":"J Vasc Surg"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/SLA.0000000000002074","article-title":"Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis","volume":"265","author":"Q Guo","year":"2017","journal-title":"Ann Surg"},{"issue":"13","key":"ref25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"D Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1538-7836.2010.03892.x","article-title":"Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study","volume":"8","author":"V V Kakkar","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"16","key":"ref28","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.2022015796","article-title":"Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer","volume":"140","author":"C Becattini","year":"2022","journal-title":"Blood"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","article-title":"Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial","volume":"3","author":"S R Guntupalli","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"48M","DOI":"10.1016\/S0002-9149(00)01481-8","article-title":"Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial","volume":"86","author":"A G Turpie","year":"2000","journal-title":"Am J Cardiol"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"A Leizorovicz","year":"2004","journal-title":"Circulation"},{"issue":"7537","key":"ref33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"A T Cohen","year":"2006","journal-title":"BMJ"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jth.14671","article-title":"The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on Hemostasis and Malignancy of the ISTH","volume":"18","author":"J I Zwicker","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004118","article-title":"Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis","volume":"5","author":"S Osataphan","year":"2021","journal-title":"Blood Adv"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"A T Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"A T Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"ref40","first-page":"2280","article-title":"Thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"A C Spyropoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial","volume":"153","author":"R D Hull","year":"2010","journal-title":"Ann Intern Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V118.21.674.674","article-title":"Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients","volume":"118","author":"A A Khorana","year":"2011","journal-title":"Blood"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"F I Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"08","key":"ref46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"A A Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"08","key":"ref47","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3390\/cancers13122905","article-title":"Primary thromboprophylaxis in patients with malignancies: daily practice recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (\u00d6GHO)","volume":"13","author":"M Kirschner","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"07","key":"ref49","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16","key":"ref50","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.22.01542","article-title":"Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems","volume":"41","author":"A Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"M Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"18","key":"ref52","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"U Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref53","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"G T Gerotziafas","year":"2017","journal-title":"Oncologist"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV Study","volume":"22","author":"C A Cella","year":"2017","journal-title":"Oncologist"},{"issue":"07","key":"ref55","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"I Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/onco.13540","article-title":"D-dimer enhances risk-targeted thromboprophylaxis in ambulatory patients with cancer","volume":"25","author":"V Kumar","year":"2020","journal-title":"Oncologist"},{"issue":"07","key":"ref57","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jtha.2023.03.037","article-title":"Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort","volume":"21","author":"C Verzeroli","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref58","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"G Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"G Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"ref60","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.22.00255","article-title":"A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts","volume":"41","author":"A Mu\u00f1oz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref61","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"A W Rutjes","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-120738","article-title":"Rivaroxaban thromboprophylaxis in high risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI)","volume":"132","author":"A A Khorana","year":"2018","journal-title":"Blood"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127917","article-title":"Analysis and cost-effectiveness analysis of low-dose direct oral anticoagulant for the prevention of cancer associated thrombosis","volume":"134","author":"A Li","year":"2019","journal-title":"Blood"},{"issue":"06","key":"ref64","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/ejh.13955","article-title":"Venous thromboembolism in metastatic pancreatic cancer","volume":"110","author":"L Laderman","year":"2023","journal-title":"Eur J Haematol"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"A Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"issue":"17","key":"ref66","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1002\/cam4.3269","article-title":"Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study","volume":"9","author":"S Vadhan-Raj","year":"2020","journal-title":"Cancer Med"},{"issue":"08","key":"ref67","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/cancers12082028","article-title":"Primary thromboprophylaxis in ambulatory pancreatic cancer patients receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"C Frere","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"e006072","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"A A Khorana","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.thromres.2022.02.022","article-title":"Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: a systematic review and meta-analysis","volume":"213","author":"M Abufarhaneh","year":"2022","journal-title":"Thromb Res"},{"issue":"06","key":"ref70","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJMc2314937","article-title":"VTE with amivantamab plus chemotherapy in NSCLC","volume":"390","author":"F Moik","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"ref71","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2023.3634","article-title":"Risk-directed ambulatory thromboprophylaxis in lung and gastrointestinal cancers: the TARGET-TP Randomized Clinical Trial","volume":"9","author":"M Alexander","year":"2023","journal-title":"JAMA Oncol"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"e12549","DOI":"10.1002\/rth2.12549","article-title":"Rivaroxaban thromboprophylaxis for gastric\/gastroesophageal junction tumors versus other tumors: a post hoc analysis of the randomized CASSINI trial","volume":"5","author":"J V Mones","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thromres.2021.03.013","article-title":"Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: a post-hoc analysis of the AVERT trial","volume":"202","author":"D Ladha","year":"2021","journal-title":"Thromb Res"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14737140.2023.2213891","article-title":"First-line treatment of multiple myeloma in both transplant and non-transplant candidates","volume":"23","author":"A Oriol","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajh.26806","article-title":"Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival","volume":"98","author":"C Charalampous","year":"2023","journal-title":"Am J Hematol"},{"issue":"07","key":"ref76","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"A Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"ref77","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"K M Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"V De Stefano","year":"2022","journal-title":"Haematologica"},{"issue":"07","key":"ref80","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.jtha.2024.03.019","article-title":"Unmet needs and barriers in venous thromboembolism education and awareness among people living with cancer: a global survey","volume":"22","author":"N Potere","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref82","doi-asserted-by":"crossref","first-page":"102173","DOI":"10.1016\/j.rpth.2023.102173","article-title":"Venous thromboembolism prevention in cancer care: implementation strategies to address underuse","volume":"7","author":"K A Martin","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s11739-023-03306-8","article-title":"Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive","volume":"18","author":"M Verso","year":"2023","journal-title":"Intern Emerg Med"},{"issue":"05","key":"ref84","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"M A de Winter","year":"2022","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/a-2145-7238","article-title":"A Novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer","volume":"124","author":"A T Cohen","year":"2024","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref86","first-page":"88","article-title":"Factor XI inhibitors: what should clinicians know","volume":"38","author":"A Pandey","year":"2023","journal-title":"Curr Opin Cardiol"},{"issue":"15","key":"ref87","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"D Gailani","year":"2024","journal-title":"Blood"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"T F Wang","year":"2019","journal-title":"J Thromb Haemost"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2374-3425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T23:13:20Z","timestamp":1746659600000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2374-3425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":83,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,5,4]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2374-3425","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}